Effects of Sildenafil on the Gastrocnemius and Cardiac Muscles of Rats in a Model of Prolonged Moderate Exercise Training

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Rinaldi, Barbara ^a   Donniacuo, Maria ^a   Sodano, Loredana ^a   Gritti, Giulia ^a   Signoriello, Simona ^a   Parretta, Elisabetta ^a   Berrino, Liberato ^a   Urbanek, Konrad ^a   Capuano, Annalisa ^a   Rossi, Francesco ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATROGIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MUSCLE RING FINGER 1 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SILDENAFIL; TRANSCRIPTION FACTOR FKHRL1; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXERCISE; GASTROCNEMIUS MUSCLE; HEART EJECTION FRACTION; HEART HYPERTROPHY; HEART MUSCLE; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; MUSCLE ATROPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYSICAL PERFORMANCE; RAT;

ANIMALS; BLOTTING, WESTERN; FORKHEAD TRANSCRIPTION FACTORS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MITOCHONDRIA, MUSCLE; MUSCLE PROTEINS; MUSCLE, SKELETAL; MYOCARDIUM; PHYSICAL CONDITIONING, ANIMAL; PIPERAZINES; PURINES; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONES; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880785267     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069954     Document Type: Article

References (45)

1. Gielen S, Schuler G, Adams V, (2010) Cardiovascular effects of exercise training: molecular mechanisms. Circulation 122: 1221-1238.
2. Timmons JA, (2011) Variability in training-induced skeletal muscle adaptation. J Appl Physiol 110: 846-853.
3. Marini M, Falcieri E, Margonato V, Treré D, Lapalombella R, et al. (2008) Partial persistence of exercise-induced myocardial angiogenesis following 4-week detraining in the rat. Histochem Cell Biol 129: 479-487.
4. Laughlin MH, Bowles DK, Duncker DJ, (2012) The coronary circulation in exercise training. Am J Physiol Heart Circ Physiol 302: H10-23.
5. Little JP, Safdar A, Benton CR, Wright DC, (2011) Skeletal muscle and beyond: the role of exercise as a mediator of systemic mitochondrial biogenesis. Appl Physiol Nutr Metab 36: 598-607.
6. Stepto NK, Benziane B, Wadley GD, Chibalin AV, Canny BJ, et al. (2012) Short-term intensified cycle training alters acute and chronic responses of PGC-1α and cytochrome c oxidase IV to exercise in human skeletal muscle. PLOS one 7: e53080.
7. Linke A, Erbs S, Hambrecht R, (2008) Effects of exercise training upon endothelial function in patients with cardiovascular disease. Front Biosci 13: 424-432.
8. Szostak J, Laurant P, (2011) The forgotten face of regular physical exercise: a 'natural' anti-atherogenic activity. Clin Sci (Lond) 121: 91-106.
9. Harrold LR, Gurwitz JH, Field TS, Andrade SE, Fish LS, et al. (2000) The diffusion of a novel therapy into clinical practice: the case of sildenafil. Arch Intern Med 160: 3401-3405.
10. Kulkarni SK, Patil CS, (2004) Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol. 26: 789-799.
11. Lin CS, Lin G, Xin ZC, Lue TF, (2006) Expression, distribution and regulation of phosphodiesterase 5. Curr Pharm Des 12: 3439-3457.
12. Kukreja RC, Salloum F, Das A, Ockaili R, Yin C, et al. (2005) Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascul Pharmacol 42: 219-232.
13. Kirsch M, Kemp-Harper B, Weissmann N, Grimminger F, Schmidt HH, (2008) Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signalling. FASEB J 22: 30-40.
14. Di Luigi L, Sgrò P, Baldari C, Gallotta MC, Emerenziani GP, et al. (2012) The phosphodiesterases type 5 inhibitor tadalafil reduces the activation of the hypothalamus-pituitary-adrenal axis in men during cycle ergometric exercise. Am J Physiol Endocrinol Metab 302: E972-978.
15. Milano G, Bianciardi P, Rochemont V, Vassalli G, Segesser LK, et al. (2011) Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium. PLoS One 6: e27910. Erratum in PLoS One. 2012;7(1). doi:--10.1371/annotation/f7aebee7-7b7e-4a44-aa23-56e9a32f14f6.
16. Guazzi M, Vicenzi M, Arena R, Guazzi MD, (2011) PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 4: 8-17.
17. Kukreja RC, Salloum FN, Das A, Koka S, Ockaili RA, et al. (2011) Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp Clin Cardiol 16: e30-35.
18. Kloner RA, (2004) Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 110: 3149-3155.
19. Hsu AR, Barnholt KE, Grundmann NK, Lin JH, McCallum SW, et al. (2006) Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. J Appl Physiol 100: 2031-2040.
20. Colahan PT, Jackson CA, Rice B, Szabo N, Jones JH (2010) The effect of sildenafil citrate administration on selected physiological parameters of exercising Thoroughbred horses. Equine Vet J Suppl 38: 606-612.
21. Finck BN, Kelly DP, (2006) PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. Clin Invest 116: 615-622.
22. Adhihetty PJ, Uguccioni G, Leick L, Hidalgo J, Pilegaard H, et al. (2009) The role of PGC-1alpha on mitochondrial function and apoptotic susceptibility in muscle. Am J Physiol Cell Physiol 297: C217-225.
23. Ventura-Clapier R, Garnier A, Veksler V, (2008) Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res 79: 208-17.
24. Arany Z, (2008) PGC-1 coactivators and skeletal muscle adaptations in health and disease. Curr Opin Genet Dev 18: 426-434.
25. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, et al. (2008) HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451: 1008-1012.
26. Borniquel S, García-Quintáns N, Valle I, Olmos Y, Wild B, et al. (2010) Inactivation of Foxo3a and subsequent downregulation of PGC-1 alpha mediate nitric oxide-induced endothelial cell migration. Mol Cell Biol 30: 4035-4044.
27. Le Brasseur NK, Walsh K, Arany Z, (2011) Metabolic benefits of resistance training and fast glycolytic skeletal muscle. Am J Physiol Endocrinol Metab 300: E3-10.
28. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, et al. (2006) PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A 103: 16260-16265.
29. Geng T, Li P, Yin X, Yan Z, (2011) PGC-1α promotes nitric oxide antioxidant defenses and inhibits FOXO signalling against cardiac cachexia in mice. Am J Pathol 178: 1738-1748.
30. Tang K, Xia FC, Wagner PD, Breen EC, (2010) Exercise-induced VEGF transcriptional activation in brain, lung and skeletal muscle. Respir Physiol Neurobiol 170: 16-22.
31. Rinaldi B, Corbi G, Boccuti S, Filippelli W, Rengo G, et al. (2006) Exercise training affects age-induced changes in SOD and heat shock protein expression in rat heart. Exp Gerontol 41: 764-770.
32. Lightfoot TJ, Turner MJ, Debate KA, Kleeberger SR, (2001) Interstarin variation in murine aerobic capacity. Med Sci Sports Exerc 33: 2053-2057.
33. Kubota Y, Umegaki K, Kagota S, Tanaka N, Nakamura K, et al. (2006) Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Biol Pharm Bull 29: 1756-1758.
34. Rinaldi B, Donniacuo M, Esposito E, Capuano A, Sodano L, et al. (2011) PPARα mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure. Br J Pharmacol 163: 609-623.
35. Hettmansperger TP, McKean JW (2011). Robust Nonparametric Statistical Methods, 2nd Ed. Chapman Hall, New York.
36. Sugawara J, Komine H, Miyazawa T, Imai T, Fisher JP, et al. (2012) Impact of chronic exercise training on the blood pressure response to orthostatic stimulation. J Appl Physiol 112: 1891-1896.
37. Gomes P, Simão S, Silva E, Pinto V, Amaral JS, et al. (2009) Aging increases oxidative stress and renal expression of oxidant and antioxidant enzymes that are associated with an increased trend in systolic blood pressure. Oxid Med Cell Longev 2: 138-145.
38. Lachance D, Plante E, Bouchard-Thomassin AA, Champetier S, Roussel E, et al. (2009) Moderate exercise training improves survival and ventricular remodeling in an animal model of left ventricular volume overload. Circ Heart Fail 2: 437-445.
39. Taylor EB, Lamb JD, Hurst RW, Chesser DG, Ellingson WJ, et al. (2005) Endurance training increases skeletal muscle LKB1 and PGC-1alpha protein abundance: effects of time and intensity. Am J Physiol Endocrinol Metab 289: E960-968.
40. Sandri M (2008) Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 23: 160-170. Review.
41. Lin J, Handschin C, Spiegelman BM (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1: 361-370. Review.
42. Prior BM, Yang HT, Terjung RL, (2004) What makes vessels grow with exercise training? J Appl Physiol 97: 1119-1128.
43. Milkiewicz M, Pugh CW, Egginton S, (2004) Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice. J Physiol 560: 21-26.
44. Pyriochou A, Zhou Z, Koika V, Petrou C, Cordopatis P, et al. (2007) The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway. J Cell Physiol 211: 197-204.
45. Koneru S, Varma Penumathsa S, Thirunavukkarasu M, Vidavalur R, Zhan L, et al. (2008) Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1. J Cell Mol Med 12: 2651-2664.